PROCEPT BioRobotics Beheer
Beheer criteriumcontroles 3/4
De CEO PROCEPT BioRobotics is Reza Zadno, benoemd in Feb2020, heeft een ambtstermijn van 4.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.09M, bestaande uit 10.1% salaris en 89.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.26% van de aandelen van het bedrijf, ter waarde $ 12.53M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 3.4 jaar.
Belangrijke informatie
Reza Zadno
Algemeen directeur
US$6.1m
Totale compensatie
| Percentage CEO-salaris | 10.1% |
| Dienstverband CEO | 4.8yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 4.8yrs |
| Gemiddelde ambtstermijn bestuur | 3.4yrs |
Recente managementupdates
Recent updates
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102
Oct 31
Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth
Sep 12Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Procept Biorobotics announces $52M debt refinancing
Oct 10Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems
Sep 19Procept BioRobotics Has Resources To Ramp Up Commercialization
Sep 01Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
May 26Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues
May 10Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$100m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$103m |
| Dec 31 2023 | US$6m | US$613k | -US$106m |
| Sep 30 2023 | n/a | n/a | -US$107m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$98m |
| Dec 31 2022 | US$4m | US$575k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$77m |
| Jun 30 2022 | n/a | n/a | -US$69m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$1m | US$490k | -US$60m |
| Sep 30 2021 | n/a | n/a | -US$57m |
| Jun 30 2021 | n/a | n/a | -US$55m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$4m | US$435k | -US$53m |
Compensatie versus markt: De totale vergoeding ($USD 6.09M ) Reza } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.91M ).
Compensatie versus inkomsten: De vergoeding van Reza is gestegen terwijl het bedrijf verliesgevend is.
CEO
Reza Zadno (69 yo)
4.8yrs
Tenure
US$6,088,813
Compensatie
Dr. Reza Zadno, Ph D., has been the President, Chief Executive Officer and Director at Procept Biorobotics Corporation since February 2020. Dr. Zadno served as the Chief Executive Officer at Avedro, Inc. f...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 4.8yrs | US$6.09m | 0.26% $ 12.5m | |
| Executive VP & CFO | 6.1yrs | US$2.67m | 0.11% $ 5.3m | |
| EVP, Chief Legal Officer & Corporate Secretary | 6.3yrs | US$2.19m | 0.031% $ 1.5m | |
| Executive VP & Chief Commercial Officer | 5.7yrs | US$2.63m | 0.014% $ 686.2k | |
| Senior Vice President of Operations | no data | geen gegevens | geen gegevens | |
| Executive VP of Technology & Clinical Development | less than a year | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief People Officer | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 2.8yrs | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
48yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PRCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 4.8yrs | US$6.09m | 0.26% $ 12.5m | |
| Chairperson of the Board | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 13.3yrs | US$277.64k | 1.49% $ 71.9m | |
| Independent Director | 3.9yrs | US$254.92k | 0.24% $ 11.7m | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 3.1yrs | US$242.16k | 0.015% $ 711.7k | |
| Independent Director | 2.9yrs | US$244.92k | 0.017% $ 820.0k | |
| Independent Director | 9.4yrs | US$247.42k | 0.31% $ 15.1m | |
| Independent Director | 3.4yrs | US$252.42k | 0.0087% $ 419.1k |
3.4yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PRCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).